Evidence map›Paper›PMID 27879469›Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis2018

Frequency of Common VKORC1 Polymorphisms and Their Impact on Warfarin Dose Requirement in Pakistani Population.

Aisha Qayyum, Muzammil Hasan Najmi, Qaisar Mansoor, Muhammad Irfan, Abdul Khaliq Naveed, Andleeb Hanif, Ali Raza Kazmi, Muhammad Ismail

Open access · bronzeAbstract read
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Single nucleotide polymorphisms onInternational journal of molecular epidemiology and genetics · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Aisha Qayyum1 Department of Pharmacology, Fazaia Medical College, Air University, Islamabad, Pakistan.
Muzammil Hasan Najmi2 Department of Pharmacology, Foundation University Medical College, Islamabad, Pakistan.
Qaisar Mansoor3 Institute of Biomedical and Genetic Engineering, Islamabad, Pakistan.
Muhammad Irfan4 Department of Zoology, Pir Mehr Ali Shah Arid Agriculture University, Rawalpindi, Pakistan.
Abdul Khaliq Naveed5 Department of Biochemistry, Islamic International Medical College, Riphah International University, Rawalpindi, Pakistan.
Andleeb Hanif3 Institute of Biomedical and Genetic Engineering, Islamabad, Pakistan.
Ali Raza Kazmi3 Institute of Biomedical and Genetic Engineering, Islamabad, Pakistan.
Muhammad Ismail3 Institute of Biomedical and Genetic Engineering, Islamabad, Pakistan.
Institute of Biomedical and Genetic Engineering · PKAir University · PKFoundation University Medical College · PKPir Mehr Ali Shah Arid Agriculture University · PKRiphah International University · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polymorphisms in vitamin K epoxide reductase complex subunit 1 (VKORC1) gene lead to interindividual variability in warfarin dose requirement. The characterization of genotype frequency distribution is required in different populations for construction of customized dosing algorithms to enhance the efficacy and reduce the toxicity of warfarin therapy. This study was carried out in Pakistani population to evaluate the contribution of common VKORC1 polymorphisms to warfarin therapy. A total of 550 stable patients taking warfarin were enrolled after medical history, physical examination, and laboratory investigations. Single blood sample was collected after informed consent. Genomic DNA was extracted and genotype analysis for VKORC1 1173C>T and VKORC1-1639G>A polymorphisms was done by polymerase chain reaction-restriction fragment length polymorphism assay. A number of samples were also analyzed by direct DNA sequencing for validation of results. Data were analyzed using SPSS version 20. Genotype frequency distributions of VKORC1 1173C>T and VKORC1-1639G>A were found to be different from other populations. Both of these polymorphisms did not demonstrate significant effect on warfarin dose requirement. Although Cytochrome P450 2C9 (CYP2C9) and VKORC1 polymorphisms together attributed only 3.8% variability in warfarin dose but it was statistically significant ( p value = .004). It is concluded that there is a need to study genotype frequency distribution and their effect on warfarin dose variability among different populations due to diversity in outcome. At the same time, no effect on warfarin dose variation explained by VKORC1 polymorphisms and small variability explained by studied genotypes stresses the need for exploration of more genetic and nongenetic factors in Pakistani population.

Indexed as

Gene FrequencyAdultAgedDose-Response Relationship, DrugDrug Dosage CalculationsFemaleGenotypeHumansMaleMiddle AgedPakistanPharmacogeneticsPolymorphism, GeneticVitamin K Epoxide ReductasesWarfarinYoung AdultVitamin K Epoxide ReductasesVKORC1 protein, humanWarfarinCYP2C9 polymorphismdirect DNA sequencingPCR-RFLPVKORC1 1173C>TVKORC1–1639G>AWarfarin

Identifiers

PMID27879469
PMCPMC6714692
OpenAlexW2439051932

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.